Skip to main content
    V

    Vertex Pharmaceuticals Inc (VRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $517.49
    -6.44 (-1.23%)

    Market Cap: $132.80B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(33/39)
    Avg Surprise
    +11.50%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.20
    Range$-29.51 - $5.06
    12 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$4.91-124.4%
    60d ago$4.91-124.4%
    30d ago$-2.35+48.9%
    7d ago$-1.22+1.6%
    Current$-1.20
    Revenue Consensus
    $3.4B
    Range$3.3B - $3.5B
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$8.34
    Range$-10.57 - $11.46
    15 analysts
    Revenue Consensus
    $3.6B
    Range$3.5B - $3.7B
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$8.34---
    Sep 26EST
    		-$-1.20---
    Jun 26
    Reported Aug 3
    		$4.20$4.15+1.20%Beat-7.1%
    Mar 26
    Reported May 4
    		$4.47$4.31+3.81%Beat+10.1%
    Dec 25
    Reported Feb 12
    		$5.03$5.15-2.33%Miss+26.4%
    Sep 25
    Reported Nov 3
    		$4.80$4.58+4.80%Beat+9.6%
    Jun 25
    Reported Aug 4
    		$4.52$4.25+6.35%Beat+135.2%
    Mar 25
    Reported May 5
    		$4.06$4.29-5.36%Miss-14.7%
    Dec 24
    Reported Feb 10
    		$3.98$4.02-0.99%Miss-5.2%
    Sep 24
    Reported Nov 4
    		$4.38$4.13+6.05%Beat+7.4%
    Jun 24
    Reported Aug 1
    		$-12.83$-11.75-9.19%Miss-429.8%
    Mar 24
    Reported May 6
    		$4.76$4.06+17.24%Beat+56.1%
    Dec 23
    Reported Feb 5
    		$4.20$4.09+2.69%Beat+11.7%
    Sep 23
    Reported Nov 6
    		$4.08$3.97+2.77%Beat+1.7%
    Jun 23
    Reported Aug 1
    		$3.89$3.88+0.26%Beat+8.1%
    Mar 23
    Reported May 1
    		$3.05$3.00+1.67%Beat-13.4%
    Dec 22
    Reported Feb 7
    		$3.76$3.51+7.12%Beat+11.6%
    Sep 22
    Reported Oct 27
    		$4.01$3.64+10.16%Beat+12.6%
    Jun 22
    Reported Aug 4
    		$3.60$3.50+2.86%Beat+15.8%
    Mar 22
    Reported May 5
    		$3.52$3.54-0.56%Miss+18.1%
    Dec 21
    Reported Jan 26
    		$3.37$3.29+2.43%Beat+34.3%
    Sep 21
    Reported Nov 2
    		$3.56$3.07+15.96%Beat+34.8%
    Jun 21
    Reported Jul 29
    		$3.11$2.38+30.67%Beat+19.2%
    Mar 21
    Reported Apr 29
    		$2.98$2.69+10.78%Beat+16.4%
    Dec 20
    Reported Feb 1
    		$2.51$2.55-1.57%Miss+47.6%
    Sep 20
    Reported Oct 29
    		$2.64$2.33+13.30%Beat+114.6%
    Jun 20
    Reported Jul 30
    		$2.61$2.08+25.48%Beat+107.1%
    Mar 20
    Reported Apr 29
    		$2.56$1.85+38.38%Beat+124.6%
    Dec 19
    Reported Jan 30
    		$1.70$1.22+39.34%Beat+30.8%
    Sep 19
    Reported Oct 30
    		$1.23$1.16+6.03%Beat+12.8%
    Jun 19
    Reported Jul 31
    		$1.26$1.07+17.76%Beat+34.0%
    Mar 19
    Reported Apr 30
    		$1.14$1.01+12.87%Beat+50.0%
    Dec 18
    Reported Feb 5
    		$1.30$1.06+22.64%Beat+113.1%
    Sep 18
    Reported Oct 24
    		$1.09$1.01+7.92%Beat+105.7%
    Jun 18
    Reported Jul 25
    		$0.94$0.75+25.33%Beat+141.0%
    Mar 18
    Reported Apr 26
    		$0.76$0.63+20.63%Beat-42.9%
    Dec 17
    Reported Jan 31
    		$0.61$0.54+12.96%Beat+74.3%
    Sep 17
    Reported Oct 25
    		$0.53$0.37+43.24%Beat-
    Jun 17
    Reported Jul 26
    		$0.39$0.36+8.33%Beat-
    Mar 17
    Reported Apr 27
    		$1.33$1.05+26.67%Beat-
    Dec 16
    Reported Jan 25
    		$0.35$0.29+20.69%Beat-

    Key Metrics

    Valuation
    P/E Ratio27.97EV/EBITDA24.93x
    Price/FCF34.58xFCF Yield2.89%
    Profitability
    Profit Margin35.00%Operating Margin38.10%
    ROE23.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage313.20x
    Current Ratio3.19xQuick Ratio2.74x
    Trading Statistics
    Beta0.28Avg Volume1.23M
    52-Week High$560.2552-Week Low$403.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$510.99
    SMA 20$510.14
    SMA 50$522.94
    SMA 200$477.61
    EMA 10$515.90
    EMA 20$513.94
    EMA 50$512.47
    EMA 200$484.75

    MACD

    Line: 0.92Signal: -1.96Hist: 2.88

    ADX

    ADX: 17.5+DI: 24.4-DI: 24.9

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down64.0
    PSAR$494.12

    Bollinger Bands

    Upper Band$533.94
    Lower Band$486.33
    %B Position933%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    51.7

    Momentum Oscillators

    Stoch %K77.1
    Stoch %D83.9
    Williams %R-37.8
    ROC (10d)2.1%
    Momentum10.49
    CCI (20d)62.3
    MFI (14d)62.1

    Volatility Measures

    ATR (14d)$13.85(2.7%)
    StdDev (20d)11.90
    Hist Vol29.7%(Moderate)

    Volume Flow

    VWAP$518.83
    OBV1.9M
    AD Line-12.6M
    CMF (20d)-0.129

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.9x
    VWMA (20d)$509.84

    Pivot Points

    R3$540.54
    R2$536.81
    R1$530.37
    Pivot Point$526.64
    S1$520.20
    S2$516.47
    S3$510.03

    Advanced Oscillators

    TSI1.57
    Ultimate Osc50.8
    KST-27.31

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.33B$2.99B$3.19B$3.08B$2.96B$2.77B$2.91B$2.77B$2.65B$2.69B$2.52B$2.48B
    Cost of Revenue$489.20M$392.80M$466.00M$414.80M$407.50M$363.00M$423.40M$392.60M$371.90M$342.60M$368.00M$318.70M
    Gross Profit$2.84B$2.59B$2.72B$2.66B$2.56B$2.41B$2.49B$2.38B$2.27B$2.35B$2.15B$2.16B
    Operating Expenses$1.60B$1.46B$1.52B$1.48B$1.41B$1.78B$1.46B$1.26B$5.79B$1.21B$1.16B$1.13B
    R&D$1.02B$962.10M$1.03B$1.03B$980.60M$999.50M$1.09B$890.90M$5.42B$865.90M$842.40M$861.70M
    SG&A$582.20M$493.70M$487.00M$445.10M$424.60M$396.40M$377.60M$371.80M$372.20M$342.70M$369.10M$263.80M
    Operating Income$1.25B$1.14B$1.21B$1.19B$1.15B$630.10M$1.03B$1.12B$-3,514,700,000$1.14B$988.50M$1.04B
    Interest Income$120.60M$114.80M$121.90M$125.70M$118.70M$117.90M$128.20M$132.20M$156.50M$181.20M$179.50M$167.90M
    Interest Expense$0$0$3.30M$3.30M$0$0$2.80M$7.50M$9.90M$10.40M$10.60M$10.90M
    Income Before Tax$1.39B$1.25B$1.33B$1.30B$1.28B$730.40M$1.14B$1.22B$-3,391,200,000$1.28B$1.15B$1.18B
    Income Tax Expense$292.00M$221.50M$139.90M$215.90M$250.10M$84.10M$223.50M$178.70M$202.40M$179.50M$178.80M$143.90M
    Net Income$1.10B$1.03B$1.19B$1.08B$1.03B$646.30M$913.00M$1.05B$-3,593,600,000$1.10B$968.80M$1.04B
    EBITDA$1.33B$1.19B$1.27B$1.23B$1.22B$660.90M$1.06B$1.15B$-3,483,800,000$1.16B$1.04B$1.06B
    EBIT$1.27B$1.14B$1.21B$1.18B$1.16B$612.50M$1.01B$1.10B$-3,537,800,000$1.11B$978.70M$1.02B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VRTX

    News

    Vertex Pharmaceuticals advances povetacicept: what it means for Vertex Pharmaceuticals stock

    Vertex Pharmaceuticals announced positive Phase 3 trial results for povetacicept, showing a 52.00% reduction in proteinuria for immunoglobulin A nephropathy patients. The drug is positioned as a potential at-home...

    ad-hoc-news.de•10/27/26•Bullish

    Rare Disease Genome Editing Market Outlook Signals Expansion To $2.88 Billion Through 2030

    The rare disease genome editing market is projected to expand significantly, from $1.29 billion in 2025 to $2.88 billion by 2030, driven by advancements in gene editing tools, increased funding...

    openPR.com•10/27/26•Bullish

    How Investors May Respond To Sarepta Therapeutics (SRPT) DM1 Therapy Progress

    Sarepta Therapeutics (SRPT) recently announced promising preclinical data for SRP-1003 in myotonic dystrophy type 1...

    Simply Wall Street•10/26/26•Neutral

    Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3

    Corxel Pharmaceuticals is set to go public via a SPAC merger with Amanat Acquisition Corp., bringing in $377 million to fund its oral GLP-1 obesity drug, CX11...

    MedCity News•10/26/26•Somewhat-Bullish

    Regeneron stock trades at 19.78 times earnings versus Vertex at 29.93

    Regeneron Pharmaceuticals (ISIN US75886F1075) is currently valued at 19.78 times earnings, significantly lower than Vertex Pharmaceuticals which trades at 29.93 times earnings. Regeneron's market capitalization stands at...

    ad-hoc-news.de•10/26/26•Neutral

    VRTX Valuation and Fair Value

    P/E
    28.0x
    Forward P/E
    24.1x
    EV/EBITDA
    24.9x
    P/FCF
    34.6x
    PEG
    1.9x
    P/B
    6.5x
    See GNG's fair value

    VRTX Profitability: Margins, ROIC and FCF

    Gross margin
    86.0%
    Operating margin
    38.1%
    Net margin
    35.0%
    ROE
    23.5%
    FCF yield
    2.9%

    VRTX Competitors

    CompanyTicker
    Intuitive Surgical IncISRG
    Bristol-Myers Squibb CompanyBMY
    Danaher CorporationDHR
    Medtronic PLCMDT
    Pfizer IncPFE
    CVS Health CorpCVS
    Novo Nordisk A/SNVO
    Stryker CorporationSYK

    Sector: Healthcare

    VRTX Analyst Ratings

    Consensus
    Buy
    Analysts
    32
    Strong Buy
    6
    Buy
    20
    Hold
    4
    Sell
    1
    Strong Sell
    1

    VRTX Bull Case vs Bear Case

    Bull case

    • VRTX has a 35.0% net profit margin.
    • VRTX grew quarterly revenue 12.5% year over year.
    • 81.3% of VRTX's analyst ratings are Buy or Strong Buy.

    VRTX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    1.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About VRTX

    Does VRTX pay dividends?

    Vertex Pharmaceuticals Inc (VRTX) does not currently pay a regular dividend.

    What is VRTX's P/E ratio?

    Vertex Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 27.97.

    What is VRTX's market cap?

    Vertex Pharmaceuticals Inc (VRTX) has a market capitalization of $132.80B with a current stock price of $517.49.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In